Literature DB >> 19824809

Cardiovascular risk assessment in antiretroviral-naïve HIV patients.

Paolo Maggi1, Tiziana Quirino, Elena Ricci, Giuseppe Vittorio L De Socio, Aurora Gadaleta, Fabrizio Ingrassia, Francesco Perilli, Antonio Lillo, Paolo Bonfanti.   

Abstract

Various studies have been conducted to evaluate the role of antiretroviral therapy in the onset of cardiovascular risk among HIV-1-infected patients, while fewer data are available regarding antiretroviral-naïve patients. Our objective was to evaluate the cardiovascular risk among naïve subjects examining traditional risk factors, immunovirologic parameters, assessing the Framingham risk score (FRS), and detecting the presence of subclinical carotid lesions by means of color Doppler ultrasonography. One hundred seventy-two antiretroviral-naïve patients underwent color Doppler ultrasonography. An intima-media thickness (IMT) greater than 0.9 mm and/or atherosclerotic plaques were considered pathologic findings. Demographic, immunovirologic data, and risk factors for cardiovascular disease were collected. The 10-year probability of acute coronary events was assessed by the FRS. The statistical analysis was performed using t test and chi(2), Fisher's test, and conditional multiple logistic. Thirty-six patients (20.9%) had lesions at ultrasonographic investigation. The presence of lesions was significantly related to male gender (p = 0.005), age (p = 0.003), sedentary life (p = 0.05), Centers for Disease Control and Prevention (CDC) group C or CD4(+) less than 150 cells/mm(3), and viral load (VL) > 100,000 copies per milliliter (p = 0.04). The presence of subclinical carotid lesions showed a highly significant direct association with the estimated FRS (p < 0.002). The presence of subclinical atheromasic lesion results was also high among antiretroviral-naïve patients. FRS is highly predictive of the lesions, but also an advanced stage of disease plays a significant role. Our data support the hypothesis that HIV infection per se is a risk factor for atherosclerosis. We recommend an ultrasonographic assessment both among patients with FRS 6% or more and among those in advanced stage of disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824809     DOI: 10.1089/apc.2009.0102

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  12 in total

1.  Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography.

Authors:  Omar Wever Pinzon; Jorge Silva Enciso; Jorge Romero; Harikrishna Makani; Jose Fefer; Vani Gandhi; Sripal Bangalore; Farooq A Chaudhry
Journal:  Circ Cardiovasc Imaging       Date:  2011-07-12       Impact factor: 7.792

2.  Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.

Authors:  Alexandra Mangili; Raabia Ahmad; Robert L Wolfert; Jeffrey Kuvin; Joseph F Polak; Richard H Karas; Christine A Wanke
Journal:  Clin Infect Dis       Date:  2013-12-11       Impact factor: 9.079

3.  Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.

Authors:  Zahedi Mujawar; Norimasa Tamehiro; Angela Grant; Dmitri Sviridov; Michael Bukrinsky; Michael L Fitzgerald
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

4.  Endothelial, inflammatory, coagulation, metabolic effects and safety of etravirine in HIV-uninfected volunteers.

Authors:  Samir K Gupta; Deming Mi; Ziyue Liu; Chandan Saha
Journal:  AIDS Patient Care STDS       Date:  2011-04-06       Impact factor: 5.078

5.  Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study.

Authors:  Giuseppe Vittorio De Socio; Elena Ricci; Giustino Parruti; Leonardo Calza; Paolo Maggi; Benedetto Maurizio Celesia; Giancarlo Orofino; Giordano Madeddu; Canio Martinelli; Barbara Menzaghi; Lucia Taramasso; Giovanni Penco; Laura Carenzi; Marco Franzetti; Paolo Bonfanti
Journal:  Infection       Date:  2016-04-05       Impact factor: 3.553

6.  HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.

Authors:  Katleen de Gaetano Donati; Roberto Cauda; Licia Iacoviello
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-11-11       Impact factor: 2.576

7.  The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study.

Authors:  Andrea De Luca; Katleen de Gaetano Donati; Manuela Colafigli; Alessandro Cozzi-Lepri; Amalia De Curtis; Andrea Gori; Laura Sighinolfi; Andrea Giacometti; Maria Rosaria Capobianchi; Alessandro D'Avino; Licia Iacoviello; Roberto Cauda; Antonella D'Arminio Monforte
Journal:  BMC Infect Dis       Date:  2013-09-03       Impact factor: 3.090

8.  Clinical factors associated with carotid plaque and intima-medial thickness in HIV-infected patients.

Authors:  Su Jin Jeong; Hye Won Kim; Nam Su Ku; Sang Hoon Han; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

9.  Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study.

Authors:  Teri-Louise Davies; Mark Gompels; Sarah Johnston; Begoña Bovill; Margaret T May
Journal:  BMJ Open       Date:  2013-10-25       Impact factor: 2.692

10.  Associations between Tobacco, Alcohol, and Drug Use with Coronary Artery Plaque among HIV-Infected and Uninfected Men in the Multicenter AIDS Cohort Study.

Authors:  Sean G Kelly; Michael Plankey; Wendy S Post; Xiuhong Li; Ronald Stall; Lisa P Jacobson; Mallory D Witt; Lawrence Kingsley; Christopher Cox; Matthew Budoff; Frank J Palella
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.